Peter Boan
Overview
Explore the profile of Peter Boan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
50
Citations
220
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Davison S, Kanitkar T, Menouhos D, Ewin T, Marshall C, Boan P, et al.
Med J Aust
. 2024 Aug;
221(5):244-245.
PMID: 39104159
No abstract available.
2.
Opdam H, Boan P, Barry L, Chapman J
Transpl Infect Dis
. 2024 Jun;
26 Suppl 1:e14315.
PMID: 38853544
Background: Systems for quality and safety assurance in organ donation and transplantation are vital, especially those that seek to minimize donor disease transmission. Australia has developed a national vigilance and...
3.
Malherbe J, Boan P, Purtill D, Wright M, Cannell P, Gangatharan S, et al.
Intern Med J
. 2024 Apr;
54(4):664-670.
PMID: 38572768
Coronavirus-19 (COVID-19) mortality rates among haemopoietic stem cell transplant (HSCT) patients are high, ranging between 20% and 40%. We prospectively evaluated the mortality outcomes of COVID-19 in Western Australian HSCT...
4.
Tan K, Boan P, Heath C
Intern Med J
. 2024 Mar;
54(3):516-517.
PMID: 38475978
No abstract available.
5.
Boan P, Jamboti J, Musk M, Lavender M, Wrobel J, Lee F, et al.
Intern Med J
. 2024 Mar;
54(4):678-681.
PMID: 38450913
We transplanted six solid organs from three hepatitis C virus (HCV) polymerase chain reaction (PCR)-positive donors during 2018-2023. Recipients were treated with glecaprevir/pibrentasvir or sofosbuvir/velpatasvir for 4-12 weeks, with all...
6.
7.
Law L, Lo W, House C, Rawlins M, Boan P, Musk M
Intern Med J
. 2023 Dec;
54(2):234-241.
PMID: 38064419
Background: Western Australia (WA) serves as a unique global case study on the impact of coronavirus disease 2019 (COVID-19) on an isolated, prepared and highly vaccinated population. This study builds...
8.
Teh B, Mikulska M, Averbuch D, de la Camara R, Hirsch H, Akova M, et al.
Lancet Infect Dis
. 2023 Sep;
24(1):e59-e68.
PMID: 37683684
Patients can be immunocompromised from a diverse range of disease and treatment factors, including malignancies, autoimmune disorders and their treatments, and organ and stem-cell transplantation. Infections are a leading cause...
9.
Kaur R, Purtill D, Cooney J, Cannell P, Wright M, Copeland T, et al.
Transpl Infect Dis
. 2023 Sep;
25 Suppl 1:e14147.
PMID: 37676725
Background: Cytomegalovirus (CMV) is a common cause of morbidity after allogeneic haematopoietic cell transplantation (alloHCT). Pre-emptive therapy (PET) with valganciclovir (VGC) is associated with haematological toxicity. Methods: We included alloHCT...
10.
House C, Rawlins M, Dyer J, Boan P, Musk M
Intern Med J
. 2023 Jul;
53(9):1548-1555.
PMID: 37493390
Background: Western Australia (WA) was in a unique position to experience coronavirus disease 2019 (COVID-19) in a highly vaccinated and geographically isolated population. Aim: To describe the COVID-19 Omicron experience...